-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
8 views
Genentech and AbbVie noted that Venclexta failed to help treat patients with newly diagnosed higher-risk MDS; However, this drug has already been approved for several other hematological indications. The 2% increase in revenue growth of the oncology portfolio was thanks to HER2 franchise; Primarily driven by 47% conversion rate in 58 launch countries by Phesgo. The decision was made to advance anti-alpha-synuclein monoclonal antibody prasinezumab into phase 3 development; Time to confirmed motor progression endpoint more pronounced in patients who took the drug alongside levodopa therapy.
